Pembrolizumab as an effective treatment for diffuse malignant peritoneal mesothelioma with long‑term survival: A case report and literature review
- Authors:
- Chongxiang Xue
- Zhe Dong
- Kexin Tan
- Xu Zhang
- Yixuan Yu
- Shuo Wang
- Jiabin Zheng
- Huijuan Cui
-
Affiliations: School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing 100029, P.R. China, Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R. China, Department of Traditional Chinese Medicine/Integrative Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan 410006, P.R. China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China, Intensive Care Unit, Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang 322000, P.R. China, Department of Integrative Oncology, China‑Japan Friendship Hospital, Beijing 100029, P.R. China - Published online on: February 13, 2025 https://doi.org/10.3892/ol.2025.14933
- Article Number: 187
-
Copyright: © Xue et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Figure 1
 |
Figure 2
 |
Figure 3
 |
Figure 4
 |
|
Kim J, Bhagwandin S and Labow DM: Malignant peritoneal mesothelioma: A review. Ann Transl Med. 5:2362017. View Article : Google Scholar : PubMed/NCBI | |
|
Moolgavkar SH, Meza R and Turim J: Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973–2005. Cancer Causes Control. 20:935–944. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Boffetta P: Epidemiology of peritoneal mesothelioma: A review. Ann Oncol. 18:985–990. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gray SG and Mutti L: Immunotherapy for mesothelioma: A critical review of current clinical trials and future perspectives. Transl Lung Cancer Res. 9 (Suppl 1):S100–S119. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jacquet P and Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 82:359–374. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et al: iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18:e143–e152. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shavelle R, Vavra-Musser K, Lee J and Brooks J: Life expectancy in pleural and peritoneal mesothelioma. Lung Cancer Int. 2017:27825902017. View Article : Google Scholar : PubMed/NCBI | |
|
Acherman YI, Welch LS, Bromley CM and Sugarbaker PH: Clinical presentation of peritoneal mesothelioma. Tumori. 89:269–273. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Su Y, Liu G, Du X and Li Y: Diffuse malignant peritoneal mesothelioma with paraneoplastic syndrome: A case report and literature review. Cancer Res Prev Treat. 49:246–250. 2022. | |
|
Kusamura S, Torres Mesa PA, Cabras A, Baratti D and Deraco M: The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 23:1468–1473. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Zheng G, Yang D, Guo X, Tian L, Song H and Liang Y: Osteopontin, GLUT1 and Ki-67 expression in malignant peritoneal mesothelioma: Prognostic implications. Intern Med J. 51:896–904. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Rizzolo A, Ah-Lan KC, Nu TNT and Alcindor T: Response to ipilimumab and nivolumab in a patient with malignant peritoneal mesothelioma. Clin Colorectal Cancer. 21:371–374. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Tang LK, Li ZK, Xiang YL, Ma DY and Du GB: Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report. Medicine (Baltimore). 102:e343492023. View Article : Google Scholar : PubMed/NCBI | |
|
Deng M, Zhang X, Xu C, Luo R, Chen L, Zhou Y and Hou Y: Clinical and pathological observation of conversion therapy for malignant peritoneal mesothelioma: A case report and literature review. Pathol Oncol Res. 29:16115772024. View Article : Google Scholar : PubMed/NCBI | |
|
Hung YP, Dong F, Watkins JC, Nardi V, Bueno R, Dal Cin P, Godleski JJ, Crum CP and Chirieac LR: Identification of ALK rearrangements in malignant peritoneal mesothelioma. JAMA Oncol. 4:235–238. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T and Deftereos G: Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Hum Pathol. 87:11–17. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bairos Menezes M, Pedroso de Lima R, Dunões I, Inácio M and Dinis R: A complete response to pembrolizumab in malignant peritoneal mesothelioma: A case report. Cureus. 16:e527162024.PubMed/NCBI | |
|
Mensi C, Mendola M, Dallari B, Sokooti M, Tabibi R, Riboldi L and Consonni D: Differences between peritoneal and pleural mesothelioma in Lombardy, Italy. Cancer Epidemiol. 51:68–73. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Borczuk AC, Cappellini GC, Kim HK, Hesdorffer M, Taub RN and Powell CA: Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene. 26:610–617. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
López-Ríos F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei PB, Hussain S, Krug L, Zakowski MF, et al: Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 66:2970–2979. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Xu C, Wang W, Zhang Y, Li Z, Song Z, Wang J, Yu J, Liu J, Zhang S, et al: Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma. Thorac Cancer. 14:2715–2731. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
National Comprehensive Cancer Network (NCCN), . Mesothelioma. Peritoneal, Version 1. NCCN; Plymouth Meeting, PA: 2021 | |
|
Marmarelis ME, Wang X, Roshkovan L, Walker S, McNulty S, Ciunci CA, Muira J, Katz SI, Cengel KA, Karakousis G and Langer CJ: Real-world outcomes of pembrolizumab in peritoneal mesothelioma. J Clin Oncol. 38 (15-suppl):e210942020. View Article : Google Scholar | |
|
Tanaka T, Miyamoto Y, Sakai A and Fujimoto N: Nivolumab for malignant peritoneal mesothelioma. BMJ Case Rep. 13:e2377212020. View Article : Google Scholar : PubMed/NCBI | |
|
Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F and Hassan R: Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the Anti-PD-L1 antibody avelumab. J Thorac Oncol. 11:1993–2005. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H and Kwon ED: B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 9:1036–1040. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Marmarelis ME, Wang X, Roshkovan L, Grady CB, Miura JT, Ginsberg MS, Ciunci CA, Egger J, Walker S, Cercek A, et al: Clinical outcomes associated with pembrolizumab monotherapy among adults with diffuse malignant peritoneal mesothelioma. JAMA Netw Open. 6:e2325262023. View Article : Google Scholar : PubMed/NCBI | |
|
Gazivoda VP, Kangas-Dick AW, Greenbaum AA, Roshal J, Chen C, Moore DF, Langan RC, Kennedy TJ, Minerowicz C and Alexander HR: Expression of PD-L1 in patients with malignant peritoneal mesothelioma: A pilot study. J Surg Res. 277:131–137. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Valmary-Degano S, Colpart P, Villeneuve L, Monnien F, M'Hamdi L, Lang Averous G, Capovilla M, Bibeau F, Laverriere MH, Verriele-Beurrier V, et al: Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study. Eur J Surg Oncol. 43:1915–1923. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
White MG, Schulte JJ, Xue L, Berger Y, Schuitevoerder D, Vining CC, Kindler HL, Husain A, Turaga KK and Eng OS: Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer. 124:564–566. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, et al: Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin cisplatin pemetrexed study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet. 387:1405–1414. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et al: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet. 397:375–386. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Selleslag DL, Geraghty RJ, Ganesan TS, Slcvin ML, Wrigley PF and Brown R: Autoimmune haemolytic anaemia associated with malignant peritoneal mesothelioma. Acta Clin Belg. 44:199–201. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Kimura N, Ogasawara T, Asonuma S, Hama H, Sawai T and Toyota T: Granulocyte-colony stimulating factor- and interleukin 6-producing diffuse deciduoid peritoneal mesothelioma. Mod Pathol. 18:446–450. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Banayan S, Hot A, Janier M, Ninet J, Zurlinden O and Billotey C: Malignant mesothelioma of the peritoneum as the cause of a paraneoplastic syndrome: Detection by 18F-FDG PET. Eur J Nucl Med Mol Imaging. 33:7512006. View Article : Google Scholar : PubMed/NCBI | |
|
Socola F, Loaiza-Bonilla A, Bustinza-Linares E, Correa R and Rosenblatt JD: Recurrent thrombotic thrombocytopenic purpura-like syndrome as a paraneoplastic phenomenon in malignant peritoneal mesothelioma: A case report and review of the literature. Case Rep Oncol Med. 2012:6193482012.PubMed/NCBI | |
|
Thakral B and Loghavi S: Marked paraneoplastic leukemoid reaction in a patient with mesothelioma mimicking a myeloid neoplasm. Blood. 135:4572020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen LY, Huang LX, Wang J, Qian Y and Fang LZ: Malignant peritoneal mesothelioma presenting with persistent high fever. J Zhejiang Univ Sci B. 12:381–384. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hermann J, Bajko G, Stajgis M, Szmeja J, Kościński T and Drews M: Fever of unknown origin: A clinical mask of malignant peritoneal mesothelioma. Contemp Oncol (Pozn). 16:596–599. 2012.PubMed/NCBI | |
|
Ishizuka K, Uehara T, Arai M, Ikeda J, Hirose Y and Ikusaka M: Medical-type peritoneal mesothelioma leading to death two months after onset of fever of unknown origin. Radiol Case Rep. 17:540–543. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L and Maio M: Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial. Lancet Oncol. 14:1104–1111. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, et al: Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 3:301–309. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, et al: Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 18:1261–1273. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Desai A, Karrison T, Rose B, Pemberton E, Hill B, Straus CM, Tan YHC, Seiwert TY and Kindler HL: Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). J Clin Oncol. 36 (15-suppl):S85652018. View Article : Google Scholar | |
|
Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, et al: Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 5:351–357. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Calabrò L, Rossi G, Morra A, Rosati C, Cutaia O, Daffinà MG, Altomonte M, Di Giacomo AM, Casula M, Fazio C, et al: Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir Med. 9:969–976. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ikushima H, Sakatani T, Ohara S, Takeshima H, Horiuchi H, Morikawa T and Usui K: Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: Case report. Medicine (Baltimore). 99:e199562020. View Article : Google Scholar : PubMed/NCBI | |
|
Kitadai R, Shimoi T, Sudo K, Noguchi E, Nagata Y, Sawada R, Takashima A, Boku N and Yonemori K: Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: A retrospective study. BMC Cancer. 21:2942021. View Article : Google Scholar : PubMed/NCBI | |
|
Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, et al: Efficacy, safety, and biomarker analysis of combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov. 11:2738–2747. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Raghav K, Liu S, Overman M, Morani A, Willette A, Fournier K and Varadhachary G: Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma. JAMA Netw Open. 4:e21199342021. View Article : Google Scholar : PubMed/NCBI | |
|
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, et al: Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 22:1530–1540. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Huang X, Hong Y, Xie SY, Liao HL, Huang HM, Liu JH and Long WJ: Malignant peritoneal mesothelioma with massive ascites as the first symptom: A case report. World J Clin Cases. 10:10317–10325. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Fujiwara Y, Takahashi Y, Okada M, Kishimoto T, Kondo S, Fujikawa K, Hayama M, Sugeno M, Ueda S, Komuro K, et al: Phase I study of tremelimumab monotherapy or in combination with durvalumab in japanese patients with advanced solid tumors or malignant mesothelioma. Oncologist. 27:e703–e722. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Peng XD, You ZY, He LX and Deng Q: Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature. World J Clin Cases. 11:5296–5302. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Sugarbaker PH: Response to Nivolumab followed by complete cytoreductive surgery with HIPEC resulted in long-term survival in a patient with sarcomatoid-predominant biphasic peritoneal mesothelioma. A case report. Int J Surg Case Rep. 107:1083592023. View Article : Google Scholar : PubMed/NCBI | |
|
Lal D, Misiura M, Adeel W and Tariq R: Brain metastases with malignant peritoneal mesothelioma: Never reported before. Cureus. 15:e437442023.PubMed/NCBI |
